Related Experiment Video
Updated: Aug 11, 2026
Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E sIgE
Published on: April 21, 2019
Serum sRAGE as a potential biomarker for pediatric bronchiolitis: a pilot study
Alberto García-Salido1, Gonzalo Oñoro, Gustavo J Melen
1Pediatric Critical Care Unit, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo 65, Madrid, Spain, citopensis@yahoo.es.
Insights
Serum soluble receptor for advanced glycation end product (sRAGE) levels were elevated in children with severe bronchiolitis. sRAGE showed an inverse correlation with disease severity, suggesting its potential as a biomarker.
Area of Science:
- Pediatric Pulmonology
- Critical Care Medicine
- Biomarker Research
Background:
- Traditional inflammatory biomarkers inadequately assess bronchiolitis severity.
- Receptor for advanced glycation end product (RAGE) and its soluble isoforms (sRAGE) are implicated in lung injury pathogenesis.
Purpose of the Study:
- To evaluate serum sRAGE levels in children with severe bronchiolitis admitted to the pediatric intensive care unit (PICU).
- To investigate the correlation between sRAGE levels and clinical evolution and traditional biomarkers in bronchiolitis.
Main Methods:
- Prospective, observational study including 37 children with bronchiolitis and 43 healthy controls.
- Assessed serum sRAGE levels and compared them between patients and controls.
- Analyzed the relationship between sRAGE levels and clinical severity scores, respiratory support, and inflammatory markers (WBC, neutrophils, CRP, procalcitonin).
Main Results:
- Mean serum sRAGE levels were significantly higher in bronchiolitis patients at PICU admission compared to controls (1,215.7 ± 535 vs 849 ± 579 pg/ml).
- A significant inverse correlation was observed between serum sRAGE levels and the Wood-Downes Score at admission (p = 0.02).
Conclusions:
- Serum sRAGE levels may be elevated in pediatric patients with bronchiolitis.
- Further large-scale clinical studies are needed to confirm sRAGE's role as a biomarker for bronchiolitis inflammation and/or lung injury.
Purpose:
Traditional inflammatory biomarkers are insufficient for the evaluation of bronchiolitis severity. Recent investigations have shown that the receptor for advanced glycation end product (RAGE) and its soluble isoforms (sRAGE) play a critical role in the pathogenesis of lung injury. Main objective was to assess the serum levels of sRAGE of children with severe bronchiolitis admitted to the pediatric intensive care unit (PICU). Secondary objective was to study sRAGE correlation with the evolution and traditional biomarkers.
Methods:
Prospective, observational and descriptive study, 43 healthy controls and 37 patients (December 2011-February 2012) were enrolled. sRAGE levels were assessed and compared. In patients, the relation between sRAGE levels and clinical evolution, respiratory assistance, white blood cell count, absolute neutrophils count, serum C-reactive protein, and serum procalcitonin was analyzed.
Results:
A statistical difference was found in the mean value of sRAGE at PICU admission between patients and controls (1,215.7 ± 535 vs 849 ± 579 pg/ml). Also a significant inverse correlation was found between sRAGE and the Wood-Downes Score at admission (p = 0.02).
Conclusions:
Serum sRAGE could be elevated in children with bronchiolitis. Larger clinical studies are necessary to elucidate its role as a bronchiolitis inflammatory and/or lung injury biomarker.
